Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects

Abstract

BackgroundThis study aimed to investigate new bone formation using recombinant human bone morphogenetic protein 2 (rhBMP-2) and locally applied bisphosphonate in rat calvarial defects.MethodsThirty-six rats were studied. Two circular 5 mm diameter bony defect were formed in the calvaria using a trephine bur. The bony defect were grafted with Bio-Oss® only (group 1, n = 9), Bio-Oss® wetted with rhBMP-2 (group 2, n = 9), Bio-Oss® wetted with rhBMP-2 and 1 mM alendronate (group 3, n = 9) and Bio-Oss® wetted with rhBMP-2 and 10 mM alendronate (group 4, n = 9). In each group, three animals were euthanized at 2, 4 and 8 weeks after surgery, respectively. The specimens were then analyzed by histology, histomorphometry and immunohistochemistry analysis.ResultsThere were significant decrease of bone formation area (p < 0.05) between group 4 and group 2, 3. Group 3 showed increase of new bone formation compared to group 2. In immunohistochemistry, collagen type I and osteoprotegerin (OPG) didn’t show any difference. However, receptor activator of nuclear factor κB ligand (RANKL) decreased with time dependent except group 4.ConclusionLow concentration bisphosphonate and rhBMP-2 have synergic effect on bone regeneration and this is result from the decreased activity of RANKL of osteoblast.

Effects of locally administered rhBMP‐2 and bisphosphonate on bone regeneration in the rat fibula

“…Group XENO_Low BP ( n = 8) were grafted with xenogenic bone (CollaOss; Bioland, Korea) locally administered in low‐concentration alendronate (1 mM; Cayman Chemical, USA), whereas group XENO_High BP ( n = 8) were grafted with xenogenic bone locally administered in high‐concentration alendronate (10 mM). The concentrations of alendronate used in this study were based on a previous study (Kim, Song, et al., ).…”

“…In previous studies, the concentration used to prevent root resorption in delayed replantation after extraction of teeth was 1 mM (0.325 mg/ml) (Komatsu et al, 2008;Levin, Bryson, Caplan, & Trope, 2001;Shibata et al, 2004). Moreover, another previous study (Kim, Song, et al, 2015) used 1 and 10 mM alendronate as low and high concentration, respectively. Thus, in this study, we used two concentrations of alendronate, 1 and 10 mM.…”

Early effect of Botox-A injection into the masseter muscle of rats: functional and histological evaluation

“…The primary antibody dilutions were as follows: MYH2, 1:50. The immunohistochemical procedures were performed as described in a previous publication [ 15 ]. The negative controls were sections stained without primary antibodies.…”

DC-STAMP: A Key Regulator in Osteoclast Differentiation

“…Collectively, our data suggest that DC‐STAMP, together with MMP‐2 and MMP‐9 (Galliera et al, ; Rocha et al, ), can be a useful tool for monitoring, in parallel with other bone turnover markers, to evaluate bone remodeling and tissue healing. Given that DC‐STAMP+ cells are homing to bone fracture sites, a step forward approach is to molecular engineer a chimeric DC‐STAMP protein by which DC‐STAMP is able to bring small peptides/proteins such as bone morphogenetic protein 2 (BMP‐2) or MMP‐9 (Kim et al, ; Matsumoto et al, ; Miller et al, ; Saito et al, ; Wang et al, ) with healing‐promoting effects to bone fracture sites.…”